Endoscopic Patch Deployment for Large-Area Ulcer Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for bleeding ulcers, such as injection, thermal, and mechanical therapies, are often expensive, time-consuming, and ineffective for larger surface areas, and gastric bypass procedures are cumbersome and less accurate.
Innovation Solution
A medical device with a handle, end cap, and actuation elements is used to deploy biocompatible patches for hemostasis, allowing precise positioning and deployment of patches within the body without repeated insertion of medical devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (injection, thermal, mechanical) are used for bleeding ulcers, then hemostasis can be achieved, but the treatment is expensive and time-consuming
Solution Approach 1:
The patent extracts the hemostatic function from complex conventional therapies and concentrates it into a simple patch delivery system. The patch contains hemostatic agents that can be directly applied to the ulcer, eliminating the need for repeated injections or complex thermal/mechanical procedures, thereby reducing procedure time while maintaining hemostasis effectiveness
Solution Approach 2:
The patch is prepared in advance with hemostatic agents and delivered to the ulcer site in a single procedure. This preliminary preparation allows the patch to be immediately effective upon deployment, avoiding the multiple steps and repeated interventions required by conventional therapies, thus reducing procedure time without compromising hemostasis
2Reliability
If conventional therapies are used for bleeding ulcers, then hemostasis can be achieved, but the treatment is expensive
Solution Approach 1:
The patent extracts the essential hemostatic function from expensive conventional therapies and implements it through a simpler patch delivery system. The patch contains concentrated hemostatic agents that can be applied once, eliminating the need for repeated expensive interventions, thereby reducing treatment cost while maintaining hemostasis effectiveness
Solution Approach 2:
The patch is designed as a disposable, single-use device that contains pre-loaded hemostatic agents. This eliminates the need for expensive reusable equipment and multiple procedural interventions, providing cost-effective hemostasis through a simple, throwaway patch that delivers the full therapeutic effect in one application
3Reliability
If conventional therapies are used for larger ulcers, then treatment can be attempted, but they cannot treat larger surface area effectively
Solution Approach 1:
The patch delivery system can deploy multiple patches or a single large patch that covers the entire ulcer surface area. This segmented or expanded patch approach allows effective treatment of larger ulcers, whereas conventional therapies struggle to cover large surfaces adequately, thereby improving hemostasis effectiveness for large-area ulcers
Solution Approach 2:
The patch transitions from a point-source application (conventional injections) to a surface-area coverage approach. The patch can be deployed to cover the entire ulcer surface in two dimensions, providing uniform hemostatic agent distribution across large areas, thereby enabling effective treatment of larger ulcers that conventional therapies cannot address
4Reliability
If gastric bypass procedure is performed for chronic ulcers, then ulcers can be treated, but the procedure is difficult, time-consuming, and less accurate
Solution Approach 1:
The patent extracts the ulcer treatment function from the complex gastric bypass procedure and implements it through a simple patch delivery system. The patch can be deployed endoscopically to treat chronic ulcers directly, eliminating the need for complex surgical bypass procedures, thereby reducing procedure complexity while maintaining treatment effectiveness
Solution Approach 2:
The patch delivers the therapeutic effect of complex procedures through a simplified model. Instead of performing the complex physiological changes of gastric bypass, the patch copies the essential outcome (ulcer healing and hemostasis) through direct local application of hemostatic agents, achieving the same therapeutic goal with minimal procedural complexity
Data Source
AI summary
A medical device includes a handle with a primary actuator and one or more secondary actuators, an end cap configured to be coupled to a distal end of another medical device and including stationary and movable portions, one or more patches that are coupled to the movable portion, one or more control elements coupling the primary actuator to the movable portion; and one or more actuation elements. The one or more actuation elements extend from the one or more secondary actuators to a position between a portion of the one or more patches and the movable portion of the end cap. Movement of the primary actuator moves the movable portion of the end cap relative to the stationary portion of the end cap, and movement of the one or more secondary actuators at least partially deploys the one or more patches from the movable portion of the end cap.